Compare PLSE & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | PHAT |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | 427 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2016 | 2019 |
| Metric | PLSE | PHAT |
|---|---|---|
| Price | $14.39 | $14.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $22.00 | $17.33 |
| AVG Volume (30 Days) | 167.2K | ★ 1.3M |
| Earning Date | 11-05-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $86,000.00 | ★ $147,190,000.00 |
| Revenue This Year | N/A | $220.82 |
| Revenue Next Year | $1,002.94 | $82.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 460.30 |
| 52 Week Low | $12.56 | $2.21 |
| 52 Week High | $25.00 | $18.31 |
| Indicator | PLSE | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 49.53 | 44.02 |
| Support Level | $13.82 | $13.14 |
| Resistance Level | $15.34 | $14.68 |
| Average True Range (ATR) | 0.78 | 1.05 |
| MACD | 0.02 | -0.20 |
| Stochastic Oscillator | 28.88 | 20.30 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.